Maternal RSV vaccine development. Where to from here?

References

• Nam HH, Ison MG. Respiratory syncytial virus infection in adults. Br Med J. 2019;366:5021. doi:10.1136/bmj.l5021.
   PubMedGoogle Scholar
• Shi T, McAllister DA, O’Brien KL, EAF S, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/s0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med. 2017;38(1):29–36. doi:10.1016/j.ccm.2016.11.010.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98. doi:10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Reeves RM, Hardelid P, Gilbert R, Warburton F, Ellis J, Pebody RG. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012. Influenza Other Respir Viruses. 2017;11(2):122–29. doi:10.1111/irv.12443.
   PubMed Web of Science ®Google Scholar
• Pierangeli A, Scagnolari C, Antonelli G. Respiratory syncytial virus. Minerva Pediatr. 2018;70(6):553–65. doi:10.23736/s0026-4946.18.05312-4.
   PubMed Web of Science ®Google Scholar
• Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther. 2014;3(2):133–58. doi:10.1007/s40121-014-0046-6.
   PubMedGoogle Scholar
• Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–69. doi:10.1002/ppul.23570.
   PubMed Web of Science ®Google Scholar
• Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM, Losada JV, Bianchi A, Acosta PL, Talarico LB, Ferretti A, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195(1):96–103. doi:10.1164/rccm.201603-0658OC.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, Groome MJ, Cohen C, Moyes J, Thorburn K, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5(10):e984–e991. doi:10.1016/s2214-109x(17)30344-3.
   PubMed Web of Science ®Google Scholar
• Wheeler SM, Dotters-Katz S, Heine RP, Grotegut CA, Swamy GK. Maternal effects of respiratory syncytial virus infection during pregnancy. Emerg Infect Dis. 2015;21(11):1951–55. doi:10.3201/eid2111.150497.
   PubMed Web of Science ®Google Scholar
• Hause AM, Panagiotakopoulos L, Weintraub ES, Sy LS, Glenn SC, Tseng HF, McNeil MM. Adverse outcomes in pregnant women hospitalized with respiratory syncytial virus infection: a case series. Clin Infect Dis. 2021;72(1):138–40. doi:10.1093/cid/ciaa668.
   PubMed Web of Science ®Google Scholar
• Regan AK, Klein NP, Langley G, Drews SJ, Buchan S, Ball S, Kwong JC, Naleway A, Thompson M, Wyant BE, et al. Respiratory syncytial virus hospitalization during pregnancy in 4 high-income countries, 2010-2016. Clin Infect Dis. 2018;67(12):1915–18. doi:10.1093/cid/ciy439.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cutland CL, Downs S, Jones S, van Niekerk N, EAF S, Nunes MC. Burden of respiratory syncytial virus infection in South African Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected pregnant and postpartum women: a longitudinal cohort study. Clin Infect Dis. 2018;66(11):1658–65. doi:10.1093/cid/cix1088.
   PubMed Web of Science ®Google Scholar
• Chu HY, Katz J, Tielsch J, Khatry SK, Shrestha L, LeClerq SC, Magaret A, Kuypers J, Steinhoff MC, Englund JA. Clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. PLOS ONE. 2016;11(3):e0152015. doi:10.1371/journal.pone.0152015.
   PubMed Web of Science ®Google Scholar
• Hause AM, Avadhanula V, Maccato ML, Pinell PM, Bond N, Santarcangelo P, Ferlic-Stark L, Ye X, Iwuchukwu O, Maurer L, et al. Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women. Vaccine. 2019;37(26):3464–71. doi:10.1016/j.vaccine.2019.04.098.
   PubMed Web of Science ®Google Scholar
• Smith DR. Herd immunity. Vet Clin North Am Food Anim Pract. 2019;35(3):593–604. doi:10.1016/j.cvfa.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine. 2015;94(21):e831. doi:10.1097/MD0000000000000831.
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28. doi:10.1056/nejm200106213442507.
   PubMed Web of Science ®Google Scholar
• Wrotek A, Kobiałka M, Grochowski B, Kamińska I, Pędziwiatr K, Skoczek-Wojciechowska A, Godek M, Jackowska T. Respiratory complications in children hospitalized with respiratory syncytial virus infection. Adv Exp Med Biol. 2020;1279:113–20. doi:10.1007/5584_2020_530.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. Expert Rev Anti Infect Ther. 2020:1–23. doi:10.1080/14787210.2021.1828866.
   Web of Science ®Google Scholar
• Tahamtan A, Askari FS, Bont L, Salimi V. Disease severity in respiratory syncytial virus infection: role of host genetic variation. Rev Med Virol. 2019;29(2):e2026. doi:10.1002/rmv.2026.
   PubMed Web of Science ®Google Scholar
• Tahamtan A, Samadizadeh S, Rastegar M, Nakstad B, Salimi V. Respiratory syncytial virus infection: why does disease severity vary among individuals? Expert Rev Respir Med. 2020;14(4):415–23. doi:10.1080/17476348.2020.1724095.
   PubMed Web of Science ®Google Scholar
• Harding JN, Siefker D, Vu L, You D, DeVincenzo J, Pierre JF, Cormier SA. Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity. BMC Microbiol. 2020;20(1):140. doi:10.1186/s12866-020-01816-5.
   PubMed Web of Science ®Google Scholar
• Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, Rovers M, Bont L. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6):e1513–1520. doi:10.1542/peds.2010-3054.
   PubMed Web of Science ®Google Scholar
• Gouyon JB, Rozé JC, Guillermet-Fromentin C, Glorieux I, Adamon L, Di Maio M, Miloradovich T, Anghelescu D, Pinquier D, Escande B, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2013;141(4):816–26. doi:10.1017/s0950268812001069.
   PubMed Web of Science ®Google Scholar
• Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis. 2009;9:106. doi:10.1186/1471-2334-9-106.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1398–408. doi:10.1016/s1473-3099(15)00247-9.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652–65. doi:10.1016/j.jmb.2007.02.024.
   PubMed Web of Science ®Google Scholar
• Alansari K, Toaimah FH, Almatar DH, El Tatawy LA, Davidson BL, Qusad MIM. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics. 2019;143:3. doi:10.1542/peds.2018-2308:.
   Web of Science ®Google Scholar
• Linnane B, Kiernan MG, O’Connell NH, Kearse L, Dunne CP. Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med. 2015;10:32. doi:10.1186/s40248-015-0029-9.
   PubMed Web of Science ®Google Scholar
• Harkensee C, Brodlie M, Embleton ND, McKean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect. 2006;52(1):2–8. doi:10.1016/j.jinf.2005.08.003.
   PubMed Web of Science ®Google Scholar
• Prescott WA Jr., Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics. 2010;28(4):279–93. doi:10.2165/11531860-000000000-00000.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620. doi:10.1542/peds.2014-1666.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, EAF S, Esser MT, Khan AA, Dubovsky F, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25. doi:10.1056/NEJMoa1913556.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–e311. doi:10.1016/s1473-3099(18)30292-5.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, EAF S, Swamy GK, Agrawal S, Ahmed K, August A, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383(5):426–39. doi:10.1056/NEJMoa1908380.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14(3):758–66. doi:10.1080/21645515.2017.1345385.
   PubMed Web of Science ®Google Scholar
• Romanin V, Acosta AM, Juarez MDV, Briere E, Sanchez SM, Cordoba BL, Sevilla ME, Lucion MF, Urrutia A, Sagradini S, et al. Maternal vaccination in Argentina: tetanus, diphtheria, and acellular pertussis vaccine effectiveness during pregnancy in preventing pertussis in infants <2 months of age. Clin Infect Dis. 2020;70(3):380–87. doi:10.1093/cid/ciz217.
   PubMed Web of Science ®Google Scholar
• Murray A, Chu HY. RSV, antibodies and the developing world. Pediatr Infect Dis. 2019;38:6S. doi:10.1097/INF.0000000000002333.
   Google Scholar
• Ciobanu AM, Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM. Benefits and risks of IgG transplacental transfer. Diagnostics (Basel). 2020;10:8. doi:10.3390/diagnostics10080583.
   Google Scholar
• Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, Andrews N. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis. 2016;63(suppl 4):s236–s243. doi:10.1093/cid/ciw559.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, Cam DH, Khatry SK, LeClerq SC, et al. Breast milk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis. 2019;219(1):59–67. doi:10.1093/infdis/jiy477.
   PubMed Web of Science ®Google Scholar
• Hogan AB, Campbell PT, Blyth CC, Lim FJ, Fathima P, Davis S, Moore HC, Glass K. Potential impact of a maternal vaccine for RSV: a mathematical modelling study. Vaccine. 2017;35(45):6172–79. doi:10.1016/j.vaccine.2017.09.043.
   PubMed Web of Science ®Google Scholar
• GSK starts phase 3 study of RSV maternal candidate vaccine [press release]. GlaxoSmithKline. 2020 Nov 23.
   Google Scholar
• PATH. A Roadmap for advancing RSV maternal immunization. Seattle (WA): PATH; 2018.
   Google Scholar
• PATH. Advancing RSV maternal immunization: a gap analysis report. Seattle (WA): PATH; 2018.
   Google Scholar
• Krishnaswamy S, Lambach P, Giles ML. Key considerations for successful implementation of maternal immunization programs in low and middle income countries. Hum Vaccin Immunother. 2019;15(4):942–50. doi:10.1080/21645515.2018.1564433.
   PubMed Web of Science ®Google Scholar
• Giles ML, Mason E, Muñoz FM, Moran AC, Lambach P, Merten S, Diaz T, Baye M, Mathai M, Pathirana J, et al. Antenatal care service delivery and factors affecting effective tetanus vaccine coverage in low- and middle-income countries: results of the Maternal Immunisation and Antenatal Care Situational Analysis (MIACSA) project. Vaccine. 2020;38(33):5278–85. doi:10.1016/j.vaccine.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Giles ML, Mantel C, Muñoz FM, Moran A, Roos N, Yusuf N, Diaz T, Ahun M, Nic Lochlainn LM, Wootton E, et al. Vaccine implementation factors affecting maternal tetanus immunization in low- and middle-income countries: results of the Maternal Immunization and Antenatal Care Situational Analysis (MIACSA) project. Vaccine. 2020;38(33):5268–77. doi:10.1016/j.vaccine.2020.05.084.
   PubMed Web of Science ®Google Scholar